marketcaparena
Search

    IDYA

    IDEAYA Biosciences, Inc.

    Company overview

    Market capitalization
    $3.69B
    Employees
    145
    Latest publication
    2026-09-29
    About IDEAYA Biosciences, Inc.

    IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20232023-06-30 · USDQ3 20222022-09-30 · USDQ3 20202020-09-30 · USD
    Total Revenue207,834,000USD0USD0USD7,000,000USD0USD3,544,000USD29,699,000USD8,967,000USD
    Cost Of Revenue82,993,000USD74,226,000USD70,886,000USD643,000USD1,012,000USD998,000USD925,000USD284,000USD
    Gross Profit124,841,000USD-74,226,000USD-70,886,000USD6,357,000USD-1,012,000USD2,546,000USD28,774,000USD8,683,000USD
    Research Development82,993,000USD74,226,000USD70,886,000USD140,183,000USD57,152,000USD29,178,000USD22,372,000USD10,024,000USD
    Selling General Administrative16,389,000USD14,580,000USD13,503,000USD10,955,000USD9,741,000USD7,075,000USD6,667,000USD3,939,000USD
    Unclassified Operating Expenses-82,993,000USD-74,226,000USD-70,886,000USD—-1,012,000USD———
    Total Operating Expenses16,389,000USD14,580,000USD13,503,000USD150,495,000USD65,881,000USD35,255,000USD28,114,000USD13,663,000USD
    Operating Income108,452,000USD-88,806,000USD-84,389,000USD-144,138,000USD-66,893,000USD-32,709,000USD660,000USD-4,996,000USD
    Interest Income10,792,000USD11,315,000USD12,211,000USD13,826,000USD15,072,000USD4,783,000USD955,000USD70,000USD
    Net Interest Income10,792,000USD11,315,000USD12,211,000USD13,826,000USD15,072,000USD4,783,000USD955,000USD70,000USD
    Income Before Tax119,244,000USD-77,491,000USD-71,405,000USD-130,312,000USD-51,821,000USD-27,926,000USD1,615,000USD-4,926,000USD
    Net Income119,244,000USD-77,491,000USD-71,405,000USD-130,312,000USD-51,821,000USD-27,926,000USD1,615,000USD-4,926,000USD
    Net Income From Continuing Ops119,244,000USD-77,491,000USD-71,405,000USD-130,312,000USD-51,821,000USD-27,926,000USD1,615,000USD-4,926,000USD
    Ebit119,244,000USD-77,491,000USD-71,405,000USD-130,312,000USD-51,821,000USD-27,926,000USD1,615,000USD-4,926,000USD
    Ebitda120,274,000USD-76,258,000USD-70,272,000USD-129,669,000USD-50,809,000USD-26,928,000USD2,540,000USD-4,626,000USD
    Depreciation And Amortization1,030,000USD1,233,000USD1,133,000USD643,000USD1,012,000USD998,000USD925,000USD300,000USD
    Reconciled Depreciation1,030,000USD1,233,000USD1,133,000USD643,000USD1,012,000USD998,000USD925,000USD347,000USD
    Total Other Income Expense Net10,792,000USD11,315,000USD12,984,000USD13,826,000USD15,072,000USD4,783,000USD955,000USD70,000USD
    Income Tax Expense—————-998,000USD-955,000USD-347,000USD
    Net Income Applicable To Common Shares—————-27,926,000USD1,615,000USD-4,926,000USD
    Interest Expense——————955,000USD70,000USD
    Non Operating Income Net Other——————955,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20172017-12-31 · USD
    Total Revenue50,931,000USD27,941,000USD19,538,000USD0USD0USD
    Cost Of Revenue2,101,000USD1,725,000USD39,698,000USD1,245,000USD391,000USD
    Gross Profit50,931,000USD27,941,000USD19,538,000USD-1,245,000USD-391,000USD
    Research Development89,536,000USD58,158,000USD39,698,000USD34,319,000USD12,384,000USD
    Selling General Administrative23,897,000USD20,051,000USD15,184,000USD9,952,000USD2,054,000USD
    Total Operating Expenses113,433,000USD78,209,000USD54,882,000USD44,271,000USD14,047,000USD
    Operating Income-62,502,000USD-50,268,000USD-35,344,000USD-44,271,000USD-14,438,000USD
    Interest Income3,847,000USD506,000USD849,000USD2,288,000USD150,000USD
    Interest Expense3,847,000USD506,000USD849,000USD0USD0USD
    Net Interest Income3,847,000USD506,000USD849,000USD2,288,000USD150,000USD
    Income Before Tax-58,655,000USD-49,762,000USD-34,495,000USD-41,975,000USD-11,862,000USD
    Income Tax Expense-3,847,000USD-2,231,000USD-2,230,000USD-3,533,000USD-150,000USD
    Net Income-54,808,000USD-47,531,000USD-32,265,000USD-38,442,000USD-11,862,000USD
    Net Income From Continuing Ops-58,655,000USD-49,762,000USD-34,495,000USD-41,975,000USD-11,862,000USD
    Ebit-62,502,000USD-50,268,000USD-35,344,000USD-44,271,000USD-11,862,000USD
    Ebitda-60,401,000USD-48,543,000USD-33,963,000USD-43,026,000USD-11,471,000USD
    Depreciation And Amortization2,101,000USD1,725,000USD1,381,000USD1,245,000USD391,000USD
    Reconciled Depreciation2,101,000USD1,725,000USD1,381,000USD1,245,000USD391,000USD
    Total Other Income Expense Net3,847,000USD506,000USD849,000USD2,296,000USD2,576,000USD
    Non Operating Income Net Other3,847,000USD506,000USD849,000USD——
    Net Income Applicable To Common Shares-58,655,000USD-49,762,000USD-34,495,000USD-41,975,000USD-11,862,000USD
    Minority Interest————0USD
    Discontinued Operations————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Assets1,030,348,000USD1,109,324,000USD1,185,136,000USD1,041,270,000USD1,100,641,000USD1,124,091,000USD1,239,873,000USD973,663,000USD
    Other Current Assets18,346,000USD21,366,000USD15,761,000USD15,864,000USD15,364,000USD13,391,000USD12,165,000USD11,520,000USD
    Total Liab93,081,000USD86,390,000USD93,102,000USD81,617,000USD76,506,000USD64,944,000USD59,455,000USD42,005,000USD
    Total Stockholder Equity937,267,000USD1,022,934,000USD1,092,034,000USD959,653,000USD1,024,135,000USD1,059,147,000USD1,180,418,000USD931,658,000USD
    Other Current Liab43,745,000USD40,892,000USD45,748,000USD37,750,000USD32,907,000USD30,352,000USD28,092,000USD24,250,000USD
    Common Stock9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD8,000USD
    Capital Stock9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD9,000USD8,000USD
    Retained Earnings-835,078,000USD-736,539,000USD-653,266,000USD-772,510,000USD-695,019,000USD-622,841,000USD-492,529,000USD-440,708,000USD
    Cash157,522,000USD112,825,000USD298,927,000USD114,645,000USD129,996,000USD84,378,000USD400,283,000USD183,049,000USD
    Cash And Short Term Investments671,201,000USD639,388,000USD786,894,000USD669,738,000USD692,508,000USD676,319,000USD920,029,000USD701,658,000USD
    Total Current Assets696,107,000USD666,727,000USD802,655,000USD685,602,000USD707,872,000USD689,713,000USD932,214,000USD713,179,000USD
    Total Current Liabilities64,831,000USD58,815,000USD64,509,000USD55,338,000USD50,846,000USD46,071,000USD40,659,000USD40,742,000USD
    Net Debt-128,922,000USD-57,336,000USD-271,682,000USD-88,048,000USD-104,028,000USD-65,207,000USD-381,487,000USD-181,180,000USD
    Short Term Debt350,000USD339,000USD328,000USD318,000USD308,000USD298,000USD—606,000USD
    Short Long Term Debt Total28,600,000USD55,489,000USD27,245,000USD26,597,000USD25,968,000USD19,171,000USD18,796,000USD1,869,000USD
    Long Term Investments301,713,000USD410,297,000USD349,960,000USD322,131,000USD358,665,000USD405,832,000USD280,128,000USD251,071,000USD
    Short Term Investments513,679,000USD526,563,000USD487,967,000USD555,093,000USD562,512,000USD591,941,000USD519,746,000USD518,609,000USD
    Net Receivables6,560,000USD5,973,000USD———3,000USD20,000USD1,000USD
    Accounts Payable20,736,000USD17,584,000USD18,433,000USD17,270,000USD17,631,000USD15,421,000USD12,567,000USD15,886,000USD
    Property Plant Equipment Net31,247,000USD31,285,000USD31,716,000USD32,732,000USD33,299,000USD27,741,000USD26,620,000USD8,427,000USD
    Property Plant Equipment Gross46,192,000USD45,541,000USD45,406,000USD45,739,000USD45,599,000USD39,452,000USD37,769,000USD19,214,000USD
    Accumulated Other Comprehensive Income-494,000USD2,267,000USD2,052,000USD1,521,000USD1,585,000USD812,000USD3,836,000USD-1,416,000USD
    Common Stock Shares Outstanding88,699,754shares88,582,694shares89,690,878shares88,472,000shares88,356,000shares87,340,758shares86,188,510shares77,962,730shares
    Non Current Assets Total334,241,000USD442,597,000USD382,481,000USD355,668,000USD392,769,000USD434,378,000USD307,659,000USD260,484,000USD
    Non Current Liabilities Total28,250,000USD27,575,000USD28,593,000USD26,279,000USD25,660,000USD18,873,000USD18,796,000USD1,263,000USD
    Non Currrent Assets Other1,281,000USD1,015,000USD805,000USD805,000USD805,000USD805,000USD911,000USD986,000USD
    Net Working Capital631,276,000USD607,912,000USD738,146,000USD630,264,000USD657,026,000USD643,642,000USD891,555,000USD672,437,000USD
    Unclassified Non Current Liabilities28,250,000USD27,575,000USD28,593,000USD26,279,000USD25,660,000USD18,873,000USD18,796,000USD1,263,000USD
    Unclassified Equity1,772,821,000USD1,757,188,000USD1,743,230,000USD1,730,624,000USD1,717,551,000USD1,681,158,000USD1,669,093,000USD1,373,766,000USD
    Current Deferred Revenue——490,000USD—————
    Inventory———————1USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,109,324,000USD1,124,091,000USD649,316,000USD387,969,000USD381,347,000USD298,269,000USD113,001,000USD96,541,000USD
    Other Current Assets21,366,000USD13,391,000USD7,500,000USD5,414,000USD3,123,000USD3,143,000USD2,698,000USD706,000USD
    Total Liab86,390,000USD64,944,000USD28,226,000USD38,514,000USD79,833,000USD99,995,000USD12,601,000USD145,489,000USD
    Total Stockholder Equity1,022,934,000USD1,059,147,000USD621,090,000USD349,455,000USD301,514,000USD198,274,000USD100,400,000USD-48,948,000USD
    Other Current Liab40,892,000USD30,352,000USD18,756,000USD16,999,000USD12,320,000USD8,534,000USD5,086,000USD3,996,000USD
    Common Stock9,000USD9,000USD7,000USD5,000USD4,000USD3,000USD2,000USD1,000USD
    Capital Stock9,000USD9,000USD7,000USD5,000USD4,000USD3,000USD2,000USD0USD
    Retained Earnings-736,539,000USD-622,841,000USD-348,364,000USD-235,403,000USD-176,748,000USD-126,986,000USD-92,491,000USD-50,516,000USD
    Cash112,825,000USD84,378,000USD157,018,000USD68,632,000USD92,046,000USD72,037,000USD34,067,000USD20,505,000USD
    Cash And Short Term Investments639,388,000USD676,319,000USD525,114,000USD364,829,000USD246,770,000USD283,585,000USD98,956,000USD89,961,000USD
    Total Current Assets666,727,000USD689,713,000USD532,632,000USD370,454,000USD250,996,000USD288,605,000USD101,654,000USD90,667,000USD
    Total Current Liabilities58,815,000USD46,071,000USD27,101,000USD31,718,000USD45,159,000USD38,640,000USD6,940,000USD5,413,000USD
    Net Debt-84,911,000USD-65,207,000USD-154,146,000USD-65,150,000USD-86,865,000USD-65,314,000USD-27,295,000USD-20,505,000USD
    Short Term Debt339,000USD298,000USD1,747,000USD1,871,000USD1,699,000USD1,540,000USD1,145,000USD0USD
    Short Long Term Debt Total27,914,000USD19,171,000USD2,872,000USD3,482,000USD5,181,000USD6,723,000USD6,772,000USD—
    Long Term Investments410,297,000USD405,832,000USD107,492,000USD8,317,000USD121,293,000USD0USD1,526,000USD0USD
    Short Term Investments526,563,000USD591,941,000USD368,096,000USD296,197,000USD154,724,000USD211,548,000USD64,889,000USD69,456,000USD
    Net Receivables5,973,000USD3,000USD18,000USD211,000USD1,103,000USD1,877,000USD——
    Accounts Payable17,584,000USD15,421,000USD6,598,000USD4,280,000USD2,100,000USD953,000USD709,000USD1,417,000USD
    Property Plant Equipment Net31,285,000USD27,741,000USD8,410,000USD8,993,000USD8,661,000USD9,476,000USD9,699,000USD5,152,000USD
    Property Plant Equipment Gross45,541,000USD39,452,000USD18,021,000USD16,546,000USD14,258,000USD4,271,000USD9,699,000USD5,152,000USD
    Accumulated Other Comprehensive Income2,267,000USD812,000USD562,000USD-2,871,000USD-712,000USD7,000USD65,000USD-31,000USD
    Common Stock Shares Outstanding88,485,238shares81,678,069shares57,519,929shares41,444,696shares35,252,443shares24,721,775shares20,233,412shares14,240,901shares
    Non Current Assets Total442,597,000USD434,378,000USD116,684,000USD17,515,000USD130,351,000USD9,664,000USD11,347,000USD5,874,000USD
    Non Current Liabilities Total27,575,000USD18,873,000USD1,125,000USD6,796,000USD34,674,000USD61,355,000USD5,661,000USD140,076,000USD
    Non Currrent Assets Other1,015,000USD805,000USD782,000USD205,000USD397,000USD188,000USD122,000USD722,000USD
    Net Working Capital607,912,000USD643,642,000USD505,531,000USD338,736,000USD205,837,000USD249,965,000USD94,714,000USD85,254,000USD
    Unclassified Non Current Liabilities27,575,000USD18,873,000USD1,125,000USD-5,185,000USD-31,192,000USD5,171,000USD5,593,000USD137,708,000USD
    Unclassified Equity1,757,188,000USD1,681,158,000USD968,878,000USD587,719,000USD478,966,000USD325,247,000USD192,822,000USD1,598,000USD
    Inventory——532,614,000USD-8,317,000USD-121,293,000USD——0USD
    Unclassified Current Assets——-532,614,000USD—————
    Other Liab———5,185,000USD31,192,000USD56,172,000USD34,000USD1,685,000USD
    Other Assets———205,000USD397,000USD188,000USD122,000USD722,000USD
    Current Deferred Revenue———8,568,000USD29,040,000USD27,613,000USD5,023,000USD299,000USD
    Non Current Liabilities Other———6,796,000USD34,674,000USD12,000USD34,000USD113,000USD
    Net Tangible Assets———349,455,000USD301,514,000USD198,274,000USD100,400,000USD-48,948,000USD
    Unclassified Current Liabilities——————-5,023,000USD—
    Intangible Assets———————0USD
    Deferred Long Term Liab———————570,000USD
    Good Will———————0USD
    Short Long Term Debt———————0USD
    Long Term Debt———————0USD
    Additional Paid In Capital———————0USD
    Treasury Stock———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-98,539,000USD-83,273,000USD119,244,000USD-77,491,000USD-72,178,000USD-130,312,000USD-51,821,000USD-52,772,000USD
    Depreciation1,143,000USD1,197,000USD1,030,000USD1,233,000USD1,133,000USD643,000USD1,012,000USD1,097,000USD
    Stock Based Compensation14,536,000USD11,793,000USD12,217,000USD11,868,000USD10,237,000USD9,485,000USD9,215,000USD9,734,000USD
    Other Non Cash Items-1,211,000USD-1,524,000USD-1,982,000USD-2,692,000USD-3,778,000USD-1,940,000USD-5,363,000USD-6,640,000USD
    Change In Working Capital8,901,000USD-18,689,000USD11,705,000USD4,608,000USD4,244,000USD469,000USD-2,277,000USD15,699,000USD
    Total Cash From Operating Activities-75,170,000USD-90,496,000USD142,214,000USD-62,474,000USD-60,342,000USD-121,655,000USD-49,234,000USD-32,882,000USD
    Capital Expenditures-967,000USD-333,000USD-42,000USD-663,000USD-1,330,000USD-1,102,000USD-457,000USD-973,000USD
    Free Cash Flow-76,137,000USD-90,829,000USD142,172,000USD-63,137,000USD-61,672,000USD-122,757,000USD-49,691,000USD-33,855,000USD
    Investments119,919,000USD-97,193,000USD41,767,000USD45,918,000USD79,817,000USD-197,109,000USD-20,036,000USD68,557,000USD
    Total Cashflows From Investing Activities118,952,000USD-97,526,000USD41,767,000USD45,918,000USD79,817,000USD-197,109,000USD-20,036,000USD68,557,000USD
    Total Cash From Financing Activities1,181,000USD2,130,000USD301,000USD1,205,000USD26,143,000USD2,753,000USD286,504,000USD39,183,000USD
    Sale Purchase Of Stock-9,000USD—————9,400,000USD—
    Change In Cash44,697,000USD-186,102,000USD184,282,000USD-15,351,000USD45,618,000USD-316,011,000USD217,234,000USD74,858,000USD
    Begin Period Cash Flow112,825,000USD298,927,000USD115,450,000USD129,996,000USD85,183,000USD401,194,000USD183,960,000USD109,102,000USD
    End Period Cash Flow157,522,000USD112,825,000USD299,732,000USD114,645,000USD130,801,000USD85,183,000USD401,194,000USD183,960,000USD
    Unclassified Financing Cash Flow1,190,000USD2,176,000USD———-9,400,000USD-9,400,000USD—
    Issuance Of Capital Stock—-46,000USD-83,000USD-25,000USD25,009,000USD8,995,000USD274,663,000USD36,321,000USD
    Other Cashflows From Investing Activities——41,809,000USD——-196,007,000USD-19,579,000USD-352,646,000USD
    Other Cashflows From Financing Activities——301,000USD1,230,000USD1,134,000USD3,158,000USD286,504,000USD2,862,000USD
    Unclassified Investing Cash Flow——-41,767,000USD—1,330,000USD197,109,000USD20,036,000USD353,619,000USD
    Change To Account Receivables—————17,000USD-19,000USD14,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Net Income-113,698,000USD-274,477,000USD-112,961,000USD-34,346,000USD-11,862,000USD
    Depreciation4,593,000USD3,834,000USD4,008,000USD886,000USD391,000USD
    Stock Based Compensation46,115,000USD34,746,000USD18,489,000USD950,000USD136,000USD
    Other Non Cash Items-9,976,000USD-23,233,000USD-11,553,000USD4,109,000USD-2,426,000USD
    Change To Account Receivables0USD15,000USD193,000USD-1,877,000USD-1,877,000USD
    Change In Working Capital1,868,000USD11,546,000USD-13,207,000USD1,654,000USD1,564,000USD
    Total Cash From Operating Activities-71,098,000USD-247,584,000USD-115,224,000USD-27,620,000USD-12,224,000USD
    Capital Expenditures-2,368,000USD-3,857,000USD-2,368,000USD-1,708,000USD-1,757,000USD
    Free Cash Flow-73,466,000USD-251,441,000USD-117,592,000USD-29,328,000USD-13,981,000USD
    Investments72,344,000USD-502,559,000USD-56,789,000USD-61,471,000USD-8,927,000USD
    Total Cashflows From Investing Activities69,976,000USD-502,559,000USD-158,456,000USD-63,179,000USD-8,927,000USD
    Total Cash From Financing Activities29,779,000USD677,551,000USD362,717,000USD105,378,000USD17,490,000USD
    Issuance Of Capital Stock24,855,000USD663,629,000USD181,832,000USD105,358,000USD—
    Change In Cash28,447,000USD-72,592,000USD89,037,000USD14,579,000USD-3,661,000USD
    Begin Period Cash Flow84,378,000USD157,775,000USD68,738,000USD6,032,000USD9,693,000USD
    End Period Cash Flow112,825,000USD85,183,000USD157,775,000USD20,611,000USD6,032,000USD
    Other Cashflows From Investing Activities69,976,000USD——-61,471,000USD-7,170,000USD
    Other Cashflows From Financing Activities29,779,000USD23,322,000USD52,954,000USD105,378,000USD17,490,000USD
    Unclassified Investing Cash Flow-69,976,000USD—-99,299,000USD61,471,000USD8,927,000USD
    Unclassified Financing Cash Flow-24,855,000USD-9,400,000USD127,931,000USD-105,449,000USD-17,490,000USD
    Change To Inventory——-2,282,000USD0USD0USD
    Change To Liabilities———322,000USD254,000USD
    Net Borrowings———0USD0USD
    Dividends Paid———0USD0USD
    Sale Purchase Of Stock———105,449,000USD17,490,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.